Vivira receives growth financing for digital therapy for musculoskeletal disorders

The Berlin-based digital health company Vivira Health Lab has concluded growth financing. The investors include IBB Capital, BONVENTURE and Patrick Palacin. Vivira intends to use the fresh capital to further expand its position as a provider of digital therapies for musculoskeletal disorders and drive forward its integration into everyday healthcare.

Digital therapy as an answer to supply bottlenecks

Musculoskeletal disorders are among the most common health problems in Germany. According to the Robert Koch Institute, around 60 percent of the population suffers from back pain every year. At the same time, there are considerable bottlenecks in the provision of physiotherapy. This is caused by a shortage of specialists and long waiting times, among other things.

Vivira is tackling this with digital movement therapies that patients can carry out at home. The applications have been clinically validated and are reimbursed by statutory health insurance companies and many private insurers.

Integration into everyday medical practice

A central focus of the company is the integration of its solutions into the daily practice of registered doctors. Vivira can be prescribed nationwide and thus complements traditional forms of therapy. According to the company, the current funding underlines the increasing acceptance of digital health applications in the regular healthcare system.

The need for digital therapy solutions is enormous, and the extent of underuse is huge. We all know people who have been unable to work for a long time because of back pain

Dr. Philip Heimann, Co-Founder & CEO Vivira

In future, Vivira wants to make greater use of artificial intelligence. The aim is to improve treatment success, increase treatment adherence and use medical data more efficiently and in compliance with the law. CEO Philip Heimann sees this as a key lever for the further development of digital, evidence-based medicine.

Expansion of offering and reach

The investment will be used in three areas in particular: the expansion of care, the development of further digital therapies and the expansion of the product portfolio in the area of musculoskeletal health.

In the long term, the company plans to expand its solutions not only in Germany, but also internationally.

Investors see social and economic added value

The investors emphasize both the medical benefits and the growth potential of the company. Stefan Sonnenberg highlights the importance of digital solutions for healthcare, while Angela Lawaldt emphasizes the demonstrable therapeutic effects and the active involvement of patients. With the new financing, Vivira intends to further consolidate its role as an established provider in the field of digital therapeutics.